Cowen & Co. Believes Dicerna Pharma (DRNA) Still Has Room to Grow


In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Dicerna Pharma (NASDAQ: DRNA). The company’s shares opened today at $13.77, close to its 52-week high of $15.80.

According to TipRanks.com, Baral is a top 25 analyst with an average return of 35.8% and a 57.8% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Dicerna Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $14.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.80 and a one-year low of $2.69. Currently, Dicerna Pharma has an average volume of 617.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. It is focused on the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.

Read More on DRNA:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts